Rationale and early clinical data on IL-17 blockade in psoriasis

References

• Hughes JE, Barraclough BM, Hamblin LG, White JE. Psychiatric symptoms in dermatology patients. Br. J. Psychiatry 143, 51–54 (1983).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137(3), 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 14(4), 267–271 (2000).
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gladman D, Gelfand JM et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 58(6), 1031–1042 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int. J. Dermatol. 32(3), 188–190 (1993).
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J. Eur. Acad. Dermatol. Venereol. 15(1), 16–17 (2001).
   PubMed Web of Science ®Google Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J. Am. Acad. Dermatol. 60(2), 218–224 (2009).
   PubMed Web of Science ®Google Scholar
• Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann. Rheum. Dis. 70(Suppl. 1), i77–i84 (2011).
   PubMed Web of Science ®Google Scholar
• Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 4(7), 441–447 (2003).
   PubMed Web of Science ®Google Scholar
• Prey S, Paul C, Bronsard V et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J. Eur. Acad. Dermatol. Venereol. 24(Suppl. 2), 31–35 (2010).
   PubMed Web of Science ®Google Scholar
• Shai A, Vardy D, Zvulunov A. Psoriasis, biblical afflictions and patients’ dignity. Harefuah 141(5), 479–82, 496 (2002).
   PubMedGoogle Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263–271 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller W, Herrmann B. Cyclosporin A for psoriasis. N. Engl. J. Med. 301(10), 555 (1979).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256(22), 3110–3116 (1986).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Grossman RM, Khandke L et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98(3), 302–309 (1992).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br. Med. J. (Clin. Res. Ed). 293(6549), 731–732 (1986).
   PubMed Web of Science ®Google Scholar
• Prens EP, van Joost T, Hegmans JP, Hooft-Benne K, Ysselmuiden OE, Benner R. Effects of cyclosporine on cytokines and cytokine receptors in psoriasis. J. Am. Acad. Dermatol. 33(6), 947–953 (1995).
   PubMed Web of Science ®Google Scholar
• Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11(1), 43–49 (2005).
   PubMed Web of Science ®Google Scholar
• Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 109(9), 1139–1142 (2002).
   PubMed Web of Science ®Google Scholar
• Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. 115(1), 81–87 (2000).
   PubMed Web of Science ®Google Scholar
• Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104(1), 9–19 (2001).
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199(1), 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123(6), xiv–xxv (2004).
   PubMed Web of Science ®Google Scholar
• Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br. J. Dermatol. 153(5), 911–918 (2005).
   PubMed Web of Science ®Google Scholar
• Pietrzak AT, Zalewska A, Chodorowska G et al. Cytokines and anticytokines in psoriasis. Clin. Chim. Acta 394(1–2), 7–21 (2008).
   PubMed Web of Science ®Google Scholar
• Rømer J, Hasselager E, Nørby PL, Steiniche T, Thorn Clausen J, Kragballe K. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. 121(6), 1306–1311 (2003).
   PubMed Web of Science ®Google Scholar
• Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111(4), 645–649 (1998).
   PubMed Web of Science ®Google Scholar
• Witowski J, Ksiazek K, Jörres A. Interleukin-17: a mediator of inflammatory responses. Cell. Mol. Life Sci. 61(5), 567–579 (2004).
   PubMed Web of Science ®Google Scholar
• Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α. J. Immunol. 162(1), 494–502 (1999).
   PubMed Web of Science ®Google Scholar
• Rich BE, Kupper TS. Cytokines: IL-20 – a new effector in skin inflammation. Curr. Biol. 11(13), R531–R534 (2001).
   Google Scholar
• Wolk K, Witte E, Warszawska K et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39(12), 3570–3581 (2009).
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80(2), 273–290 (2007).
   PubMed Web of Science ®Google Scholar
• Capon F, Di Meglio P, Szaub J et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122(2), 201–206 (2007).
   PubMed Web of Science ®Google Scholar
• Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin. Immunol. 146(2), 131–139 (2013).
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 226, 57–79 (2008).
   PubMed Web of Science ®Google Scholar
• Hofstetter H, Gold R, Hartung HP. Th17 cells in MS and experimental autoimmune encephalomyelitis. Int. MS J. 16(1), 12–18 (2009).
   PubMedGoogle Scholar
• Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16(10), 1808–1813 (2010).
   PubMed Web of Science ®Google Scholar
• Crispín JC, Liossis SN, Kis-Toth K et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16(2), 47–57 (2010).
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 549–553 (2009).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med. 361(5), 496–509 (2009).
   PubMed Web of Science ®Google Scholar
• Conrad C, Boyman O, Tonel G et al. α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13(7), 836–842 (2007).
   PubMed Web of Science ®Google Scholar
• Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 21(4), 467–476 (2004).
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71(1), 1–8 (2002).
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159(5), 1092–1102 (2008).
   PubMed Web of Science ®Google Scholar
• Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Invest. Dermatol. 129(9), 2175–2183 (2009).
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131(3), 677–687 (2011).
   PubMed Web of Science ®Google Scholar
• Puzenat E, Bronsard V, Prey S et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J. Eur. Acad. Dermatol. Venereol. 24(Suppl. 2), 10–16 (2010).
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 58(5), 826–850 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675–1684 (2008).
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P et al.; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362(2), 118–128 (2010).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol. 132(2), 304–314 (2012).
   PubMed Web of Science ®Google Scholar
• Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165(3), 661–668 (2011).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165(3), 652–660 (2011).
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365(17), 1586–1596 (2011).
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306(8), 864–871 (2011).
   PubMed Web of Science ®Google Scholar
• Nakajima K, Kanda T, Takaishi M et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186(7), 4481–4489 (2011).
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T et al.; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52–72 (2010).
   Web of Science ®Google Scholar
• Antoniu SA. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. Expert Opin. Investig. Drugs 21(11), 1607–1618 (2012).
   PubMed Web of Science ®Google Scholar
• Papp KA, Reid C, Foley P et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a Phase I, randomized, placebo-controlled trial. J. Invest. Dermatol. 132(10), 2466–2469 (2012).
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181–1189 (2012).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190–1199 (2012).
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci DP et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, Phase II regimen-finding study. Br. J. Dermatol. doi:10.1111/bjd.12070 (2012) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Spuls PI, Hooft L. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br. J. Dermatol. 167(4), 710–713; discussion 714 (2012).
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S et al.; Secukinumab in Crohn’s Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12), 1693–1700 (2012).
   PubMed Web of Science ®Google Scholar